Form 4 for LGND LIGAND PHARMACEUTICALS INC
Accepted 2022-05-13 00:00:00 ET · period of report 2022-05-13 · accession 0000886163-22-000062 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-05-13 | 2022-05-13 | LGND | FOEHR MATTHEW W | Pres, COO | P - Purchase | $82.76 | +2,500 | 173.4K | +1% | +$206.9K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-05-13 | P | A | 2,500 | $82.76 | 173,354 | D | — | — |